Martin Huber
2023 - Xilio Therapeutics
In 2023, Martin Huber earned a total compensation of $1M as Former President and Head of R&D at Xilio Therapeutics, a 24% decrease compared to previous year.
Compensation breakdown
| Option Awards | $655,365 |
|---|---|
| Salary | $358,666 |
| Other | $15,725 |
| Total | $1,029,756 |
Huber received $655.4K in option awards, accounting for 64% of the total pay in 2023.
Huber also received $358.7K in salary and $15.7K in other compensation.
Rankings
In 2023, Martin Huber's compensation ranked 1,118th out of 2,647 executives tracked by ExecPay. In other words, Huber earned more than 57.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,118 out of 2,647 | 58th |
Division Manufacturing | 668 out of 1,447 | 54th |
Major group Chemicals And Allied Products | 446 out of 817 | 45th |
Industry group Drugs | 435 out of 783 | 44th |
Industry Pharmaceutical Preparations | 294 out of 555 | 47th |
Source: SEC filing on April 25, 2024.
Huber's colleagues
We found three more compensation records of executives who worked with Martin Huber at Xilio Therapeutics in 2023.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Xilio Therapeutics CEO René Russo's 2023 pay jumps 36% to $3M
April 25, 2024
Xilio Therapeutics CEO René Russo's 2022 pay falls 60% to $2.2M
April 25, 2023
Xilio Therapeutics CEO René Russo's 2021 pay jumps 118% to $5.5M
April 26, 2022